The objective is to promote action on the prevention of rare diseases (RD) and to provide analysis and technical assistance in support of the development or implementation of a policy in the area of rare diseases and orphan drugs (OD).


EURORDIS is a patient-driven alliance of Patient Organisations (POs) and individuals active in the field of rare diseases (RD). It represents the voice of an estimated 29 million citizens in the EU.

EURORDIS mission is to build a strong pan-European community of POs and People Living With RD (PLWRD), to be their voice at the European level and to fight against the impact of RD on their lives.

To this end, EURORDIS undertakes activities on behalf of its members, notably in favour of:

• Empowering RD patient groups
• Advocating RD as a public health priority
• Raising public awareness on RD (national and international levels)
• Improving access to information, treatment, care and support for PLWRD, including support to families
• Improving quality of life
• Encouraging good practices in relation to these issues
• Promoting scientific and clinical research on RD
• Developing treatments and drugs for people with RD

EURORDIS plays a pivotal role in the definition and implementation of the EU strategy on RD (EC Communication, Dec.2008 and Council Recommendations, June 2009).


The overarching objective of the Joint Action (JA) on Health Technology Assessment (HTA), EUnetHTA Joint Action, including work on relative effectiveness assessment (REA) of pharmaceuticals is to put into practice an effective and sustainable HTA collaboration in Europe that brings added value at the European, national and regional level. The JA brings together 34 HTA agencies and institutional producers of HTA and assessments of pharmaceuticals in 24 EU and 1 EEA/EFTA country (as of November 2010). The JA facilitates solutions to overcome barriers to collaboration and facilitates national solutions to deliver context specific reporting of HTA results.


Health Action International (HAI) Europe is a non-profit, independent, European network of consumer groups, public interest NGOs, healthcare providers, academics and individuals.HAI Europe’s mission and goals follow the overarching global work programme set every 5 years.HAI Europe devises plans and strategies for medicines’ policy issues in Europe and acts as a regional centre.

HAI Europe’s mission is:
-to increase access to essential medicines = medicines for priority health needs are available, accessible and affordable for all;
-to improve the rational use of medicines = citizens receive medication appropriate to their clinical needs, in tailored doses, for an adequate period of time,at the lowest cost to them and their community.
HAI works to achieve these goals through research excellence and evidence-based advocacy.
Vision: Poverty and social injustice represent the greatest barriers to sustainable health and development. HAI works for just and equitable societies where people can participate in decisions affecting their health and well being, including the allocation of resources.


EURORDIS is a patient-driven alliance of Patient Organisations(POs) and individuals active in the field of rare diseases (RD). It represents the voice of an estimated 29 million citizens in the EU.

EURORDIS mission is to build a strong pan-European community of Patient Organisations and people living with RD, to be their voice at the European level and to fight against the impact of RD on their lives.

To this end, EURORDIS undertakes activities on behalf of its members:

• Empowering RD patient groups
• Advocating RD as a public health priority
• Raising public awareness on RD
• Improving access to information, treatment, care and support for people living with RD
• Improving quality of life
• Encouraging good practices in relation to these issues
• Promoting scientific and clinical research on RD
• Developing treatments and drugs for people with RD

EURORDIS plays a pivotal role in the implementation of the EU strategy on RD (EC Communication, Dec.2008 and Council Recommendations, June 2009), in the EU Committee of Experts on RD and in the elaboration of National Plans or Strategies on RD.
